Morgan Stanley
EVGN icon

Morgan Stanley’s Evogene EVGN Stock Holding History

Morgan Stanley’s Portfolio EVGN Stock Details EVGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.96K Sell
3,851
-5,200
-57% -$4.91K ﹤0.01% 7254
2025
Q4 		$9.96K Sell
9,051
-21,292
-70% -$24.8K ﹤0.01% 6890
2025
Q3 		$34.7K Buy
30,343
+15,157
+100% +$19.2K ﹤0.01% 6519
2025
Q2 		$19.4K Buy
15,186
+600
+4% +$734 ﹤0.01% 6658
2025
Q1 		$18.2K Hold
14,586
– – ﹤0.01% 6603
2024
Q4 		$27.3K Buy
14,586
+1,981
+16% +$3.91K ﹤0.01% 6476
2024
Q3 		$38.7K Sell
12,605
-9,241
-42% -$39.9K ﹤0.01% 6286
2024
Q2 		$142K Sell
21,846
-6,559
-23% -$45.8K ﹤0.01% 5818
2024
Q1 		$213K Sell
28,405
-9,284
-25% -$77.4K ﹤0.01% 5711
2023
Q4 		$317K Buy
37,689
+20,107
+114% +$126K ﹤0.01% 5777
2023
Q3 		$103K Buy
17,582
+4,902
+39% +$42.9K ﹤0.01% 5876
2023
Q2 		$136K Sell
12,680
-4,568
-26% -$30.9K ﹤0.01% 5811
2023
Q1 		$109K Sell
17,248
-6,693
-28% -$49.8K ﹤0.01% 5973
2022
Q4 		$168K Buy
23,941
+570
+2% +$4.02K ﹤0.01% 5741
2022
Q3 		$194K Buy
23,371
+3,657
+19% +$35.3K ﹤0.01% 5740
2022
Q2 		$151K Sell
19,714
-10,486
-35% -$103K ﹤0.01% 6029
2022
Q1 		$393K Buy
30,200
+3,735
+14% +$50.4K ﹤0.01% 5551
2021
Q4 		$434K Sell
26,465
-19,258
-42% -$437K ﹤0.01% 5631
2021
Q3 		$1.21M Sell
45,723
-44,435
-49% -$1.3M ﹤0.01% 4920
2021
Q2 		$3.08M Buy
90,158
+12,315
+16% +$482K ﹤0.01% 4263
2021
Q1 		$3.92M Buy
77,843
+52,003
+201% +$3.22M ﹤0.01% 3667
2020
Q4 		$1.22M Buy
25,840
+25,835
+516,700% +$911K ﹤0.01% 4547
2020
Q3 		$0 Hold
5
– – ﹤0.01% 6762
2020
Q2 		$0 Hold
5
– – ﹤0.01% 6638
2020
Q1 		$0 Hold
5
– – ﹤0.01% 6605
2019
Q4 		$0 Sell
5
-1,000
-100% -$14.9K ﹤0.01% 6680
2019
Q3 		$16K Sell
1,005
-1,000
-50% -$15.7K ﹤0.01% 6070
2019
Q2 		$32K Hold
2,005
– – ﹤0.01% 5778
2019
Q1 		$37K Sell
2,005
-3,267
-62% -$69.1K ﹤0.01% 5794
2018
Q4 		$105K Sell
5,272
-4,516
-46% -$114K ﹤0.01% 5538
2018
Q3 		$304K Sell
9,788
-14,011
-59% -$405K ﹤0.01% 5259
2018
Q2 		$681K Sell
23,799
-21,904
-48% -$668K ﹤0.01% 4886
2018
Q1 		$1.44M Buy
45,703
+863
+2% +$32.1K ﹤0.01% 4279
2017
Q4 		$1.38M Buy
44,840
+43,660
+3,700% +$1.71M ﹤0.01% 4334
2017
Q3 		$52K Sell
1,180
-270
-19% -$12.9K ﹤0.01% 5770
2017
Q2 		$73K Sell
1,450
-100
-6% -$5.17K ﹤0.01% 5747
2017
Q1 		$83K Sell
1,550
-275
-15% -$14.3K ﹤0.01% 5665
2016
Q4 		$93K Buy
+1,825
New +$104K ﹤0.01% 5590

Other funds holding EVGN

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
DSC
Daytona Street Capital Saint Louis, Missouri $130M AUM
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
TCM
Tradewinds Capital Management Bellingham, Washington $563M AUM 41.52% 1-Year Est. Return

Morgan Stanley's EVGN Position: Q1 2026 in Review

Morgan Stanley reduced its Evogene (EVGN) stake by 57% in Q1 2026, selling an estimated $4.91K and leaving 3,851 shares worth $2.96K. The position accounts for ﹤0.01% of the portfolio, ranked #7254.

Morgan Stanley first reported a position in EVGN in Q4 2016 and has held it in 38 quarters since. The position peaked at $3.92M in Q1 2021. 15 funds tracked by Wall St. Rank hold EVGN as of Q1 2026.

  • Morgan Stanley held 3,851 shares of Evogene worth $2.96K as of Q1 2026.
  • Morgan Stanley sold 5,200 Evogene shares in Q1 2026, an estimated $4.91K.
  • Evogene made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #7254 holding.
  • Morgan Stanley first reported a position in Evogene in Q4 2016 and has held it in 38 quarters since.
  • Morgan Stanley's Evogene position peaked at $3.92M in Q1 2021.
  • 15 funds tracked by Wall St. Rank held Evogene as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.